Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.
Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a "Buy" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.
Piper Sandler analyst Allison Bratzel also weighed in, maintaining a "Hold" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。